Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-23E73 + Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
NCT07640295Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-23E73 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Jacobio Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
JAB-23E73
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07640295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640295.